---
document_datetime: 2025-12-29 09:09:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord.html
document_name: sunitinib-accord.html
version: success
processing_time: 0.1222248
conversion_datetime: 2025-12-30 02:54:02.090824
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sunitinib Accord

[RSS](/en/individual-human-medicine.xml/67409)

##### Authorised

This medicine is authorised for use in the European Union

sunitinib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sunitinib Accord](#news-on)
- [More information on Sunitinib Accord](#more-information-on-sunitinib-accord-1606)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sunitinib Accord is a medicine used to treat adults with the following cancers:

- gastrointestinal stromal tumour (GIST), a type of cancer of the stomach and bowel where there is uncontrolled growth of cells in the supporting tissues of these organs. Sunitinib Accord is used in patients with GISTs that cannot be removed with surgery or have spread to other parts of the body. It is used after treatment with imatinib (another cancer medicine) has failed;
- metastatic renal cell carcinoma, a type of kidney cancer, that has spread to other parts of the body;
- pancreatic neuroendocrine tumours (tumours of the hormone-producing cells in the pancreas) that have spread or cannot be removed with surgery. Sunitinib Accord is used if the disease is getting worse and the tumour cells are well-differentiated (similar to normal cells in the pancreas).

Sunitinib Accord contains the active substance sunitinib and is a 'generic medicine'. This means that Sunitinib Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Sutent.

Expand section

Collapse section

## How is Sunitinib Accord used?

Sunitinib Accord can only be obtained with a prescription and treatment should be started by doctors who have experience in the use of cancer medicines.

Sunitinib Accord is available as capsules of various strengths to be taken by mouth.

For GIST and metastatic renal cell carcinoma, Sunitinib Accord is given in six-week cycles, at a dose of 50 mg once a day for four weeks, followed by a two-week 'rest period'. The dose can be adjusted according to the patient's response to the treatment, but should be kept within the range of 25 to 75 mg.

For pancreatic neuroendocrine tumours, Sunitinib Accord is given at a dose of 37.5 mg once a day without a rest period. This dose may also be adjusted.

For more information about using Sunitinib Accord, see the package leaflet or contact your doctor or pharmacist.

## How does Sunitinib Accord work?

The active substance in Sunitinib Accord, sunitinib, is a protein kinase inhibitor. This means that it blocks some specific enzymes known as protein kinases. These enzymes can be found at the surface of cancer cells, where they are involved in the growth and spread of cancer cells, and in the blood vessels that supply the tumours, where they are involved in the development of new blood vessels. By blocking these enzymes, Sunitinib Accord can reduce the growth and spread of the cancer and cut off the blood supply that keeps cancer cells growing.

## How has Sunitinib Accord been studied?

Studies on the benefits and risks of the active substance, sunitinib, in the authorised uses have already been carried out with the reference medicine, Sutent, and do not need to be repeated for Sunitinib Accord.

As for every medicine, the company provided studies on the quality of Sunitinib Accord. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Sunitinib Accord?

Because Sunitinib Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Sunitinib Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sunitinib Accord has been shown to have comparable quality and to be bioequivalent to Sutent. Therefore, the Agency's view was that, as for Sutent, the benefits of Sunitinib Accord outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sunitinib Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sunitinib Accord have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sunitinib Accord are continuously monitored. Side effects reported with Sunitinib Accord are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sunitinib Accord

Sunitinib Accord received a marketing authorisation valid throughout the EU on 11 February 2021.

Sunitinib Accord : EPAR - Medicine overview

Reference Number: EMA/18013/2021

English (EN) (158.42 KB - PDF)

**First published:** 06/04/2021

[View](/en/documents/overview/sunitinib-accord-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-775)

български (BG) (183.07 KB - PDF)

**First published:**

06/04/2021

[View](/bg/documents/overview/sunitinib-accord-epar-medicine-overview_bg.pdf)

español (ES) (158.41 KB - PDF)

**First published:**

06/04/2021

[View](/es/documents/overview/sunitinib-accord-epar-medicine-overview_es.pdf)

čeština (CS) (179.19 KB - PDF)

**First published:**

06/04/2021

[View](/cs/documents/overview/sunitinib-accord-epar-medicine-overview_cs.pdf)

dansk (DA) (156.57 KB - PDF)

**First published:**

06/04/2021

[View](/da/documents/overview/sunitinib-accord-epar-medicine-overview_da.pdf)

Deutsch (DE) (161.35 KB - PDF)

**First published:**

06/04/2021

[View](/de/documents/overview/sunitinib-accord-epar-medicine-overview_de.pdf)

eesti keel (ET) (155.43 KB - PDF)

**First published:**

06/04/2021

[View](/et/documents/overview/sunitinib-accord-epar-medicine-overview_et.pdf)

ελληνικά (EL) (182.17 KB - PDF)

**First published:**

06/04/2021

[View](/el/documents/overview/sunitinib-accord-epar-medicine-overview_el.pdf)

français (FR) (159.06 KB - PDF)

**First published:**

06/04/2021

[View](/fr/documents/overview/sunitinib-accord-epar-medicine-overview_fr.pdf)

hrvatski (HR) (185.78 KB - PDF)

**First published:**

06/04/2021

[View](/hr/documents/overview/sunitinib-accord-epar-medicine-overview_hr.pdf)

italiano (IT) (156.07 KB - PDF)

**First published:**

06/04/2021

[View](/it/documents/overview/sunitinib-accord-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (197.42 KB - PDF)

**First published:**

06/04/2021

[View](/lv/documents/overview/sunitinib-accord-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (178.04 KB - PDF)

**First published:**

06/04/2021

[View](/lt/documents/overview/sunitinib-accord-epar-medicine-overview_lt.pdf)

magyar (HU) (179.01 KB - PDF)

**First published:**

06/04/2021

[View](/hu/documents/overview/sunitinib-accord-epar-medicine-overview_hu.pdf)

Malti (MT) (189.7 KB - PDF)

**First published:**

06/04/2021

[View](/mt/documents/overview/sunitinib-accord-epar-medicine-overview_mt.pdf)

Nederlands (NL) (157.76 KB - PDF)

**First published:**

06/04/2021

[View](/nl/documents/overview/sunitinib-accord-epar-medicine-overview_nl.pdf)

polski (PL) (181.24 KB - PDF)

**First published:**

06/04/2021

[View](/pl/documents/overview/sunitinib-accord-epar-medicine-overview_pl.pdf)

português (PT) (158.62 KB - PDF)

**First published:**

06/04/2021

[View](/pt/documents/overview/sunitinib-accord-epar-medicine-overview_pt.pdf)

română (RO) (178.34 KB - PDF)

**First published:**

06/04/2021

[View](/ro/documents/overview/sunitinib-accord-epar-medicine-overview_ro.pdf)

slovenčina (SK) (178.52 KB - PDF)

**First published:**

06/04/2021

[View](/sk/documents/overview/sunitinib-accord-epar-medicine-overview_sk.pdf)

slovenščina (SL) (176.48 KB - PDF)

**First published:**

06/04/2021

[View](/sl/documents/overview/sunitinib-accord-epar-medicine-overview_sl.pdf)

Suomi (FI) (155.04 KB - PDF)

**First published:**

06/04/2021

[View](/fi/documents/overview/sunitinib-accord-epar-medicine-overview_fi.pdf)

svenska (SV) (155.98 KB - PDF)

**First published:**

06/04/2021

[View](/sv/documents/overview/sunitinib-accord-epar-medicine-overview_sv.pdf)

Sunitinib Accord : EPAR - Risk-management-plan summary

English (EN) (206.68 KB - PDF)

**First published:** 06/04/2021

[View](/en/documents/rmp-summary/sunitinib-accord-epar-risk-management-plan-summary_en.pdf)

## Product information

Sunitinib Accord : EPAR - Product Information

English (EN) (800.19 KB - PDF)

**First published:** 06/04/2021

**Last updated:** 04/12/2025

[View](/en/documents/product-information/sunitinib-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-72)

български (BG) (968.38 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/bg/documents/product-information/sunitinib-accord-epar-product-information_bg.pdf)

español (ES) (639.83 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/es/documents/product-information/sunitinib-accord-epar-product-information_es.pdf)

čeština (CS) (764.39 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/cs/documents/product-information/sunitinib-accord-epar-product-information_cs.pdf)

dansk (DA) (972.27 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/da/documents/product-information/sunitinib-accord-epar-product-information_da.pdf)

Deutsch (DE) (813.13 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/de/documents/product-information/sunitinib-accord-epar-product-information_de.pdf)

eesti keel (ET) (662.54 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/et/documents/product-information/sunitinib-accord-epar-product-information_et.pdf)

ελληνικά (EL) (1.51 MB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/el/documents/product-information/sunitinib-accord-epar-product-information_el.pdf)

français (FR) (939.12 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/fr/documents/product-information/sunitinib-accord-epar-product-information_fr.pdf)

hrvatski (HR) (814.17 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/hr/documents/product-information/sunitinib-accord-epar-product-information_hr.pdf)

íslenska (IS) (746.11 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/is/documents/product-information/sunitinib-accord-epar-product-information_is.pdf)

italiano (IT) (661.15 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/it/documents/product-information/sunitinib-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (963.25 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/lv/documents/product-information/sunitinib-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (818.45 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/lt/documents/product-information/sunitinib-accord-epar-product-information_lt.pdf)

magyar (HU) (771.41 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/hu/documents/product-information/sunitinib-accord-epar-product-information_hu.pdf)

Malti (MT) (827.48 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/mt/documents/product-information/sunitinib-accord-epar-product-information_mt.pdf)

Nederlands (NL) (621.36 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/nl/documents/product-information/sunitinib-accord-epar-product-information_nl.pdf)

norsk (NO) (600.57 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/no/documents/product-information/sunitinib-accord-epar-product-information_no.pdf)

polski (PL) (858.97 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/pl/documents/product-information/sunitinib-accord-epar-product-information_pl.pdf)

português (PT) (719.04 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/pt/documents/product-information/sunitinib-accord-epar-product-information_pt.pdf)

română (RO) (1.04 MB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/ro/documents/product-information/sunitinib-accord-epar-product-information_ro.pdf)

slovenčina (SK) (1.03 MB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/sk/documents/product-information/sunitinib-accord-epar-product-information_sk.pdf)

slovenščina (SL) (810.69 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/sl/documents/product-information/sunitinib-accord-epar-product-information_sl.pdf)

Suomi (FI) (631.14 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/fi/documents/product-information/sunitinib-accord-epar-product-information_fi.pdf)

svenska (SV) (602.99 KB - PDF)

**First published:**

06/04/2021

**Last updated:**

04/12/2025

[View](/sv/documents/product-information/sunitinib-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000269316 26/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sunitinib Accord : EPAR - All authorised presentations

English (EN) (66.31 KB - PDF)

**First published:** 06/04/2021

[View](/en/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-412)

български (BG) (60.4 KB - PDF)

**First published:**

06/04/2021

[View](/bg/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (74.41 KB - PDF)

**First published:**

06/04/2021

[View](/es/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (45.36 KB - PDF)

**First published:**

06/04/2021

[View](/cs/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (75.2 KB - PDF)

**First published:**

06/04/2021

[View](/da/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (74.56 KB - PDF)

**First published:**

06/04/2021

[View](/de/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (123.11 KB - PDF)

**First published:**

06/04/2021

[View](/et/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (92.08 KB - PDF)

**First published:**

06/04/2021

[View](/el/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (74.56 KB - PDF)

**First published:**

06/04/2021

[View](/fr/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (90.49 KB - PDF)

**First published:**

06/04/2021

[View](/hr/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (85.55 KB - PDF)

**First published:**

06/04/2021

[View](/is/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (39.37 KB - PDF)

**First published:**

06/04/2021

[View](/it/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (783.62 KB - PDF)

**First published:**

06/04/2021

[View](/lv/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (57.04 KB - PDF)

**First published:**

06/04/2021

[View](/lt/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (165.18 KB - PDF)

**First published:**

06/04/2021

[View](/hu/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (72.86 KB - PDF)

**First published:**

06/04/2021

[View](/mt/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (35.62 KB - PDF)

**First published:**

06/04/2021

[View](/nl/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (36.61 KB - PDF)

**First published:**

06/04/2021

[View](/no/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (66.66 KB - PDF)

**First published:**

06/04/2021

[View](/pl/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (37.77 KB - PDF)

**First published:**

06/04/2021

[View](/pt/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.25 KB - PDF)

**First published:**

06/04/2021

[View](/ro/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (102.53 KB - PDF)

**First published:**

06/04/2021

[View](/sk/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (44.12 KB - PDF)

**First published:**

06/04/2021

[View](/sl/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (74.04 KB - PDF)

**First published:**

06/04/2021

[View](/fi/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (69.16 KB - PDF)

**First published:**

06/04/2021

[View](/sv/documents/all-authorised-presentations/sunitinib-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sunitinib Accord Active substance sunitinib International non-proprietary name (INN) or common name sunitinib Therapeutic area (MeSH)

- Gastrointestinal Stromal Tumors
- Carcinoma, Renal Cell
- Neuroendocrine Tumors

Anatomical therapeutic chemical (ATC) code L01EX01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Gastrointestinal stromal tumour (GIST)**

Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.

**Metastatic renal cell carcinoma (MRCC)**

Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.

**Pancreatic neuroendocrine tumours (pNET)**

Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.

## Authorisation details

EMA product number EMEA/H/C/005419

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 10/12/2020 Marketing authorisation issued 11/02/2021 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sunitinib Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.21 KB - PDF)

**First published:** 06/05/2025

**Last updated:** 04/12/2025

[View](/en/documents/procedural-steps-after/sunitinib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sunitinib Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (104.24 KB - PDF)

**First published:** 14/12/2021

**Last updated:** 06/05/2025

[View](/en/documents/procedural-steps-after/sunitinib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Sunitinib Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/2430/2021

English (EN) (891.05 KB - PDF)

**First published:** 06/04/2021

[View](/en/documents/assessment-report/sunitinib-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sunitinib Accord

Adopted

Reference Number: EMA/CHMP/635286/2020

English (EN) (154.28 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sunitinib-accord_en.pdf)

#### News on Sunitinib Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

#### More information on Sunitinib Accord

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 04/12/2025

## Share this page

[Back to top](#main-content)